Researchers at the University of Liverpool have identified a unique biological “fingerprint” in adenomyosis lesions, a discovery that could lead to non-surgical treatments for the condition. Published in Science Advances, the study utilized spatial transcriptomics to map gene activity within uterine tissue, providing a roadmap for therapies that target diseased cells while preserving healthy anatomy and reproductive potential, according to the research team based in Professor Dharani Hapangama’s gynaecology research group.
What is Adenomyosis and Why Does it Matter?
Adenomyosis occurs when tissue similar to the lining of the womb grows deep into the muscle of the womb. This condition affects up to one in five women of reproductive age, according to data from the University of Liverpool. While historically associated with older patients, clinicians now recognize it as a common issue for younger women, including those who may wish to have children.
The condition is characterized by severe pain, heavy menstrual bleeding, and potential fertility complications. Despite its prevalence, patients often face limited clinical options. Current standard care remains largely restricted to hormone-based therapies—which can prevent pregnancy—or surgery to remove the womb.
Unlike previous methods, the University of Liverpool team used spatial transcriptomics. This allows scientists to see exactly which genes are active in specific cell types while keeping the tissue’s original structure intact.
How Does the New Biological Fingerprint Change Treatment?
The study found that adenomyosis lesions possess a distinct molecular profile that differentiates them from healthy uterine tissue. Dr. Alison Maclean, NIHR Clinical Lecturer, who undertook this study during her MRC clinical research training fellowship, stated that identifying these molecular markers is a step toward developing targeted therapies.
By understanding the specific biological “fingerprint” of the lesions, researchers hope to support the development of treatments that target affected areas while preserving healthy uterine tissue. The research team identified evidence of ongoing inflammation and altered energy production within the lesions. These findings suggest that existing drugs, or emerging medicines, could potentially reverse some of the biological changes observed in the lesions without the need for major surgery.
What Are the Next Steps for Clinical Application?
The transition from molecular discovery to clinical patient care requires further investigation. The researchers are currently evaluating existing and emerging drug candidates that could potentially reverse some of the biological changes observed in the lesions. The goal is to provide a “targeted” approach, preserving the uterus and protecting fertility where possible.
By focusing on the hybrid molecular identity of the lesions—which share traits with the deeper, more stable layer of the womb lining—scientists hope to understand how the disease develops and persists over time.
Pro Tip: Tracking Your Symptoms
If you suspect you have adenomyosis, keep a detailed log of your cycle length, pain intensity, and blood loss volume.
Frequently Asked Questions
How is adenomyosis different from endometriosis?
The provided sources do not contain information regarding the comparison between adenomyosis and endometriosis.
Why is surgery currently the most common treatment?
The lack of treatment choices reflects longstanding gaps in understanding the biological mechanisms that drive the disease.
Can this condition affect my ability to get pregnant?
Yes. Adenomyosis can cause fertility complications. Researchers at the University of Liverpool are specifically focusing on developing treatments that help women avoid major surgery and protect their fertility where possible.
For more updates on reproductive health research, subscribe to our newsletter or explore our archive of women’s health clinical reports. Have you or someone you know navigated a diagnosis of adenomyosis? Share your experience in the comments below.
